Cassava Sciences to Engage Investors at Major Conference Event
AUSTIN, Texas — Cassava Sciences, Inc. (NASDAQ: SAVA) is setting the stage for a key moment as it prepares for the H.C. Wainwright 27th Annual Global Investment Conference. This prominent event is slated to take place in New York City, marking a significant opportunity for the biotechnology company dedicated to treating central nervous system (CNS) disorders, including those related to Tuberous Sclerosis Complex (TSC).
Conference Participation Details
Scheduled for September 8 – 10, 2025, the conference will feature Rick Barry, the President and CEO of Cassava Sciences, participating in-person. His direct involvement emphasizes the company’s commitment to engaging with both new and existing investors while sharing its vision for innovative therapies targeted at CNS conditions.
About the H.C. Wainwright Annual Conference
This annual investment conference is renowned for attracting a diverse range of companies and investors focused on biotechnology advancements. With a format centered around corporate presentations, Cassava will be making its insights known on September 8 at 5 PM ET. This format delivers a robust platform for management to discuss the company's research initiatives and future directions.
Webcast and Replay Options
Those interested in following the presentation can access the live webcast, with a replay available on the company’s investor website for approximately 90 days post-event. This accessibility ensures that the insights shared during the conference reach a wider audience of stakeholders.
The Vision of Cassava Sciences
Cassava Sciences is primarily recognized for its pioneering work in developing investigational treatments for central nervous system disorders. Their key focus is on simufilam, a unique oral small molecule designed to modulate the activity of the filamin A protein that plays an essential role in neuronal development. This innovative approach holds promise not only for TSC-related epilepsy but potentially other significant CNS indications as well.
Company Background and Future Directions
Based in Austin, Texas, Cassava Sciences aims to lead research into therapies that could greatly enhance the quality of life for individuals suffering from CNS disorders. As the company prepares for its presentation, they are eager to illustrate their unique position in the biotech landscape. Investors can anticipate insights into clinical trials, progress reports, and advancements in simufilam’s development.
Connect with Cassava Sciences
For those looking for additional information or to engage with the company, there are direct contact options available. Sandya von der Weid has been designated for investor inquiries, while Eric Schoen, the Chief Financial Officer, is available for company-related communications.
Stay Updated
Cassava Sciences encourages ongoing dialogue with its investors, making it easier for stakeholders to stay informed about recent developments, clinical trails results, and other important news. Interested parties can reach out through the provided contact information.
Frequently Asked Questions
What is the importance of the H.C. Wainwright conference for Cassava Sciences?
The conference provides Cassava Sciences a platform to engage with investors, presenting insights into their innovative CNS disorder treatments and potential future directions.
Who is presenting at the conference?
Rick Barry, the President and CEO of Cassava Sciences, will participate in-person to highlight the company’s research and initiatives.
What is simufilam?
Simufilam is an investigational oral small molecule aimed at targeting central nervous system disorders by modulating the filamin A protein involved in neuronal development.
How can investors access the conference presentation?
Investors can access a live webcast of the presentation, with a recording available for 90 days on the Cassava Sciences investor website.
Who should I contact for investor inquiries?
Investors can reach out to Sandya von der Weid for inquiries, while Eric Schoen is available for other company-related communications.
